Beta-Blocker Selection for Atrial Fibrillation

Guideline Recommendations

The American College of Cardiology and European Heart Society list metoprolol, bisoprolol, and other beta-blockers alphabetically without preferential ranking for AF rate control, emphasizing their demonstrated efficacy during both exercise and rest 1, 2, 3
The American College of Cardiology recommends "atenolol, metoprolol, diltiazem, and verapamil (drugs listed alphabetically by class)" for rate control, emphasizing their demonstrated efficacy during both exercise and rest 1
The European Society of Cardiology provides dosing for both agents without distinguishing superiority:

Metoprolol CR/XL has specific evidence for preventing AF recurrence after cardioversion, with a randomized, placebo-controlled trial of 394 patients showing reduced relapse rates to 48.7% compared to 59.9% with placebo (p=0.005) 4
The American College of Cardiology notes that "various beta blockers have shown moderate but consistent efficacy to prevent AF recurrence," with metoprolol specifically studied for this indication 4

Beta-blockers achieve target heart rates in approximately 70% of AF patients, making them the most effective drug class for rate control 5
The European Heart Society lists metoprolol 2.5-10 mg IV bolus as a Class I recommendation for acute rate control 3
Combination therapy with digoxin may be required for adequate rate control with either agent, particularly during exercise, as beta-blocker monotherapy may not achieve target rates in all patients 6

Both bisoprolol and long-acting metoprolol are specifically recommended for AF patients with LVEF <40% by the American College of Cardiology and European Heart Society 5
The American College of Cardiology and European Heart Society identify bisoprolol, carvedilol, long-acting metoprolol, and nebivolol as the preferred beta-blockers in patients with reduced ejection fraction 5

Avoid excessive rate slowing, particularly in elderly patients with paroxysmal AF, as both agents can cause symptomatic bradycardia requiring permanent pacing 2
Target a lenient heart rate <110 bpm at rest initially rather than aggressive rate control 5
Do not use either agent as monotherapy in patients with LVEF <40% and acute decompensated heart failure—consider IV amiodarone instead for hemodynamically unstable patients 3